| P2093 | author name string | Hans Lennernäs | |
| | Per Artursson | |
| | Manfred Kansy | |
| | Li Di | |
| | Edward Kerns | |
| | Alex Avdeef | |
| | Kiyohiko Sugano | |
| | Dennis Smith | |
| | Brian Houston | |
| | Leslie Benet | |
| P2860 | cites work | Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold | Q27621019 |
| | PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations | Q27853138 |
| | A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability | Q28293773 |
| | Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes | Q28728799 |
| | Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings | Q28842973 |
| | Gabapentin enacarbil - clinical efficacy in restless legs syndrome | Q33868110 |
| | G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm Res 12, 413-420, 1995--backstory of BCS. | Q34099761 |
| | Coexistence of passive and carrier-mediated processes in drug transport | Q34128770 |
| | Molecular properties that influence the oral bioavailability of drug candidates | Q34130727 |
| | Property-based design: optimization of drug absorption and pharmacokinetics | Q34224446 |
| | Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system | Q34403502 |
| | The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. | Q34403687 |
| | Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells | Q34532617 |
| | Physicochemical selectivity of the BBB microenvironment governing passive diffusion--matching with a porcine brain lipid extract artificial membrane permeability model | Q34556508 |
| | In silico prediction of blood–brain barrier permeation | Q35557423 |
| | Transporters as a determinant of drug clearance and tissue distribution | Q36401065 |
| | Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment | Q36477445 |
| | Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1 | Q36747640 |
| | Prediction of human pharmacokinetics - renal metabolic and excretion clearance | Q36988426 |
| | The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN | Q37305906 |
| | Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans | Q37808376 |
| | Contemporary strategies for peptide macrocyclization | Q37893450 |
| | Structural modifications that alter the P-glycoprotein efflux properties of compounds | Q38002878 |
| | The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development | Q38059421 |
| | Strategies to assess blood-brain barrier penetration | Q38090672 |
| | Regional intestinal drug permeation: biopharmaceutics and drug development | Q38132545 |
| | Strategic approaches to optimizing peptide ADME properties | Q38264736 |
| | CNS drug design: balancing physicochemical properties for optimal brain exposure | Q38286160 |
| | How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets. | Q38604743 |
| | Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance | Q57112262 |
| | Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design | Q57684639 |
| | Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle | Q59355381 |
| | Impact of Dynamically Exposed Polarity on Permeability and Solubility of Chameleonic Drugs Beyond the Rule of 5 | Q62017251 |
| | Correlation of drug absorption with molecular surface properties | Q71795029 |
| | Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes | Q74448341 |
| | Absorption classification of oral drugs based on molecular surface properties | Q78896196 |
| | Computational prediction of oral drug absorption based on absorption rate constants in humans | Q83943392 |
| | Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and | Q84730477 |
| | Intracellular Drug Bioavailability: Effect of Neutral Lipids and Phospholipids | Q88513665 |
| | Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer | Q89725043 |
| | Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs | Q91088011 |
| | Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs | Q91426516 |
| | A Novel Unified Approach to Predict Human Hepatic Clearance for Both Enzyme- and Transporter-Mediated Mechanisms Using Suspended Human Hepatocytes | Q91760235 |
| | Positron Emission Tomography Imaging of [11 C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A | Q92129761 |
| | Intracellular and Intraorgan Concentrations of Small Molecule Drugs: Theory, Uncertainties in Infectious Diseases and Oncology, and Promise | Q92612848 |
| | Toward the elucidation of the mechanism for passive membrane permeability of cyclic peptides | Q92670137 |
| | ??? | Q27690215 |
| | In Vivo Predictive Dissolution (IPD) and Biopharmaceutical Modeling and Simulation: Future Use of Modern Approaches and Methodologies in a Regulatory Context. | Q38757740 |
| | Cyclic peptide oral bioavailability: Lessons from the past. | Q38834152 |
| | Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS). | Q38855314 |
| | Application of a Human Intestinal Epithelial Cell Monolayer to the Prediction of Oral Drug Absorption in Humans as a Superior Alternative to the Caco-2 Cell Monolayer | Q38909127 |
| | Permeability comparison between hepatocyte and low efflux MDCKII cell monolayer | Q38992427 |
| | Structural and conformational determinants of macrocycle cell permeability | Q39283186 |
| | pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery | Q39366999 |
| | Development of a new permeability assay using low-efflux MDCKII cells. | Q39505199 |
| | Regional Intestinal Permeability in Dogs: Biopharmaceutical Aspects for Development of Oral Modified-Release Dosage Forms | Q39513460 |
| | Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties | Q39693636 |
| | Insights From an Integrated Physiologically Based Pharmacokinetic Model for Brain Penetration. | Q40002947 |
| | Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers | Q40081558 |
| | Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B. | Q40703161 |
| | Inhibitors of NF-kappaB and AP-1 gene expression: SAR studies on the pyrimidine portion of 2-chloro-4-trifluoromethylpyrimidine-5-[N-(3', 5'-bis(trifluoromethyl)phenyl)carboxamide]. | Q40846058 |
| | Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. | Q40877910 |
| | Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line | Q41035963 |
| | Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. | Q41037826 |
| | Angiotensin-converting enzyme (ACE) inhibitor transport in human intestinal epithelial (Caco-2) cells | Q41364436 |
| | Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection. | Q41934667 |
| | The Proteome of Filter-Grown Caco-2 Cells With a Focus on Proteins Involved in Drug Disposition | Q42828712 |
| | Physicochemical determinants of passive membrane permeability: role of solute hydrogen-bonding potential and volume. | Q43770038 |
| | Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: identification of a tetrazole-containing inhibitor with cellular activity | Q43963980 |
| | Characterization of the transport of uracil across Caco-2 and LLC-PK1 cell monolayers | Q44211833 |
| | Synthesis, structure elucidation, in vitro biological activity, toxicity, and Caco-2 cell permeability of lipophilic analogues of alpha-conotoxin MII. | Q44368116 |
| | Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells | Q44443884 |
| | Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets | Q44463177 |
| | PAMPA--a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. | Q44785032 |
| | Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine* | Q44872539 |
| | A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development. | Q45267634 |
| | Demystifying brain penetration in central nervous system drug discovery. Miniperspective | Q45776855 |
| | Testing the conformational hypothesis of passive membrane permeability using synthetic cyclic peptide diastereomers. | Q46001611 |
| | Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment | Q46138795 |
| | Highly efficacious factor Xa inhibitors containing alpha-substituted phenylcycloalkyl P4 moieties | Q46220685 |
| | Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor | Q46382993 |
| | In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim | Q46485502 |
| | Jejunal permeability in humans in vivo and rats in situ: investigation of molecular size selectivity and solvent drag | Q47268173 |
| | A study on pharmacokinetics of bosentan with systems modeling, Part 2: prospectively predicting systemic and liver exposure in healthy subjects. | Q48251957 |
| | A study on pharmacokinetics of bosentan with systems modeling, Part 1: translating systemic plasma concentration to liver exposure in healthy subjects. | Q48251964 |
| | High throughput artificial membrane permeability assay for blood-brain barrier | Q48349894 |
| | The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of Parkinson's disease | Q48597050 |
| | Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers | Q48600898 |
| | Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery | Q48825227 |
| | Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin. | Q51396523 |
| | The expanding role of prodrugs in contemporary drug design and development. | Q52560078 |
| | A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography. | Q52647982 |
| | Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. | Q53417201 |
| | CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. | Q54602410 |
| | Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein. | Q54979530 |
| | Polar molecular surface properties predict the intestinal absorption of drugs in humans. | Q55067034 |
| P577 | publication date | 2020-08-02 | |
| P1433 | published in | ChemMedChem | Q2962252 |
| P1476 | title | The Critical Role of Passive Permeability in Designing Successful Drugs | |